에 대한 최신 뉴스 Danaher (NYSE:DHR) 주식

DANAHER CORP

Danaher

In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life science and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.

Stock_Whisper_Index_Logo_6-copy

Social Media

Exclusives

Tech

Trading Ideas

LAES

MRVL

SNAP

매주, 벤징가의 스톡 위스퍼 지수(Benzinga&#39;s Stock Whisper Index)는 독점 데이터(proprietary data)와 패턴 인식의 조합을 사용하여 표면 바로 아래에서 주목을 받을 만한 주식 5종목을 소개한다. 투자자들은 가치가 저평가된, 관심이 적은, 새로운 주식들을 항상 찾고 있다. 소매 거래자들이 사용할 수 있는 방법은 무수히 많기 때문에 새로운 기회를 발견하고 특정 주식이 관심을 가져야 하는 이유를 이해하기 위해 풍부한 정보를 조사하는 것이 어려운 경우가 많다.

벤징가의 &#39;스톡 위스퍼&#39; 지수: 스냅, 실스크, 버티브, 다나허 및 마벨 테크놀로지

West,Bangal,,India,-,April,20,,2022,:,Danaher,Corporation

Analyst Color

Earnings

Equities

News

Guidance

Health Care

Price Target

Reiteration

Analyst Ratings

General

화요일에, 다나허(NYSE:DHR)는 3분기 매출이 57억 9천만 달러로 전년 대비 3% 증가했으며, 컨센서스 55억 9천만 달러를 상회했다고 보고했다. 가이던스: 다나허(Danaher)는 2024 회계연도 비GAAP 핵심 매출이 전년 대비 낮은 한 자릿수로 감소할 것임을 재확인했다.

다나허의 3분기 실적은 바이오프로세싱 주문 증가로 인해 증가, 분석가는 주식 등급 유지

lockheed shutter

Movers

AVTR

CBRE

ENPH

FCNCA

LPLA

MANH

SIRI

SPOT

이들 11개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? QXO(NASDAQ:QXO)의 주가는 사모 금융 유치를 발표한 이후 33.37% 상승했다.

유니버셜 헬스 및 록히드 마틴은 지난주 최고 성과를 보여준 11개 대형주 중 일부 (7월 21일-7월 27일)

Danaher Corp

DEUTSCHE EUROSHOP UNS/ADR by Deutsche Euroshop AG

Deutsche EuroShop AG

Danaher's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) short percent of float has fallen 4.1% since its last report. The company recently reported that it has 7.45 million shares sold short, which is 1.17% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.81 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Danaher Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748872832_0_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Danaher has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Danaher's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Danaher's peer group average for short interest as a percentage of float is 7.53%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

How Do Investors Really Feel About Danaher?

SCIEX And Evosep Sign Reseller Agreement To Expand Access To Standardized High-Throughput Proteomics For Pharma And Biotech

<ul>
<li>Danaher has entered a partnership with AstraZeneca to scale precision medicine, including developing the next generation of AI-powered diagnostics</li>
<li>This partnership aims to create a framework for rapid diagnostics research, development and commercialization</li>
<li>Danaher, through its Centers for Enabling Precision Medicine, will provide support in all aspects of the development cycle across diagnostic modalities</li>
</ul>
WASHINGTON, May 29, 2025 /PRNewswire/ --&nbsp;Danaher Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) ("Danaher"), a global science and technology innovator, announced today the launch of a partnership with AstraZeneca (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) to develop and commercialize novel diagnostic tools and tests intended to help clinicians better determine which patients would most benefit from precision medicine treatments.
This partnership will utilize the newly opened Danaher Centers for Enabling Precision Medicine to support a more streamlined, end-to-end development process. The first product intended to be developed through this partnership will leverage technologies from Leica Biosystems, one of Danaher's subsidiaries. The initial focus will be on digital and computational pathology products and AI-assisted algorithms, to help clinicians better diagnose patients by identifying those who are most likely to benefit from targeted therapies.

Danaher Partners With AstraZeneca To Scale Precision Medicine, Including Developing Next Generation Of AI-Powered Diagnostics

Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) has outperformed the market over the past 10 years by 1.68% on an annualized basis producing an average annual return of 12.54%. Currently, Danaher has a market capitalization of $135.98 billion. 
Buying $100 In DHR: If an investor had bought $100 of DHR stock 10 years ago, it would be worth $325.45 today based on a price of $190.00 for DHR at the time of writing.
<h3>Danaher's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748440821_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Danaher 10 Years Ago Would Be Worth This Much Today

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CVS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/30/25</td>
<td>$59.00</td>
<td>$69.2K</td>
<td>2.4K</td>
<td>4.6K</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/30/25</td>
<td>$71.00</td>
<td>$39.1K</td>
<td>2.2K</td>
<td>4.0K</td>
</tr>
<tr>
<td>UNH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$200.00</td>
<td>$102.9K</td>
<td>4.0K</td>
<td>920</td>
</tr>
<tr>
<td>TMO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$280.00</td>
<td>$99.0K</td>
<td>1</td>
<td>650</td>
</tr>
<tr>
<td>RXRX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$7.00</td>
<td>$32.5K</td>
<td>3.5K</td>
<td>279</td>
</tr>
<tr>
<td>TEM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$65.00</td>
<td>$38.1K</td>
<td>6.6K</td>
<td>264</td>
</tr>
<tr>
<td>DHR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/19/25</td>
<td>$190.00</td>
<td>$66.9K</td>
<td>25</td>
<td>42</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/30/25</td>
<td>$36.00</td>
<td>$27.4K</td>
<td>266</td>
<td>38</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• For CVS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), we notice a put option sweep that happens to be bearish, expiring in 7 day(s) on May 30, 2025. This event was a transfer of 752 contract(s) at a $59.00 strike. This particular put needed to be split into 35 different trades to become filled. The total cost received by the writing party (or parties) was $69.2K, with a price of $92.0 per contract. There were 2468 open contracts at this strike prior to today, and today 4643 contract(s) were bought and sold. 
• Regarding NVO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), we observe a call option sweep with bearish sentiment. It expires in 7 day(s) on May 30, 2025. Parties traded 1000 contract(s) at a $71.00 strike. This particular call needed to be split into 21 different trades to become filled. The total cost received by the writing party (or parties) was $39.1K, with a price of $39.0 per contract. There were 2294 open contracts at this strike prior to today, and today 4086 contract(s) were bought and sold. 
• Regarding UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we observe a put option sweep with bullish sentiment. It expires in 238 day(s) on January 16, 2026. Parties traded 96 contract(s) at a $200.00 strike. This particular put needed to be split into 19 different trades to become filled. The total cost received by the writing party (or parties) was $102.9K, with a price of $1075.0 per contract. There were 4074 open contracts at this strike prior to today, and today 920 contract(s) were bought and sold. 
• For TMO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>), we notice a put option sweep that happens to be bullish, expiring in 210 day(s) on December 19, 2025. This event was a transfer of 150 contract(s) at a $280.00 strike. This particular put needed to be split into 34 different trades to become filled. The total cost received by the writing party (or parties) was $99.0K, with a price of $660.0 per contract. There were 1 open contracts at this strike prior to today, and today 650 contract(s) were bought and sold. 
• Regarding RXRX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>), we observe a call option trade with bearish sentiment. It expires in 602 day(s) on January 15, 2027. Parties traded 250 contract(s) at a $7.00 strike. The total cost received by the writing party (or parties) was $32.5K, with a price of $130.0 per contract. There were 3518 open contracts at this strike prior to today, and today 279 contract(s) were bought and sold. 
• Regarding TEM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>), we observe a call option sweep with bearish sentiment. It expires in 56 day(s) on July 18, 2025. Parties traded 53 contract(s) at a $65.00 strike. This particular call needed to be split into 7 different trades to become filled. The total cost received by the writing party (or parties) was $38.1K, with a price of $720.0 per contract. There were 6682 open contracts at this strike prior to today, and today 264 contract(s) were bought and sold. 
• For DHR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>), we notice a put option sweep that happens to be bearish, expiring in 210 day(s) on December 19, 2025. This event was a transfer of 34 contract(s) at a $190.00 strike. This particular put needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $66.9K, with a price of $1970.0 per contract. There were 25 open contracts at this strike prior to today, and today 42 contract(s) were bought and sold. 
• Regarding HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we observe a call option trade with bullish sentiment. It expires in 7 day(s) on May 30, 2025. Parties traded 15 contract(s) at a $36.00 strike. The total cost received by the writing party (or parties) was $27.4K, with a price of $1830.0 per contract. There were 266 open contracts at this strike prior to today, and today 38 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

Hims & Hers Health, Inc. Class A Common Stock

HIMS

RXRX

8 Health Care Stocks With Whale Alerts In Today's Session

High-rolling investors have positioned themselves bearish on Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>), and it's important for retail traders to take note. 
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in DHR often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 13 options trades for Danaher. This is not a typical pattern.
The sentiment among these major traders is split, with 30% bullish and 69% bearish. Among all the options we identified, there was one put, amounting to $32,010, and 12 calls, totaling $1,546,396.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $192.5 to $200.0 for Danaher during the past quarter. 
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Danaher's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Danaher's whale trades within a strike price range from $192.5 to $200.0 in the last 30 days. 
<h3>Danaher Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747850637_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>DHR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$11.3</td>
<td>$10.8</td>
<td>$10.8</td>
<td>$200.00</td>
<td>$540.0K</td>
<td>2.7K</td>
<td>1.5K</td>
</tr>
<tr>
<td>DHR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$11.4</td>
<td>$10.8</td>
<td>$10.8</td>
<td>$200.00</td>
<td>$132.8K</td>
<td>2.7K</td>
<td>1.0K</td>
</tr>
<tr>
<td>DHR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$11.3</td>
<td>$11.1</td>
<td>$11.3</td>
<td>$200.00</td>
<td>$131.0K</td>
<td>2.7K</td>
<td>183</td>
</tr>
<tr>
<td>DHR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$11.7</td>
<td>$11.2</td>
<td>$11.2</td>
<td>$200.00</td>
<td>$126.5K</td>
<td>2.7K</td>
<td>453</td>
</tr>
<tr>
<td>DHR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$11.4</td>
<td>$10.9</td>
<td>$10.9</td>
<td>$200.00</td>
<td>$115.5K</td>
<td>2.7K</td>
<td>605</td>
</tr>
</tbody>
</table>

<h3>About Danaher</h3>
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life science and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.
After a thorough review of the options trading surrounding Danaher, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Where Is Danaher Standing Right Now?</h3>
<ul>
<li>With a trading volume of 2,974,010, the price of DHR is down by -1.03%, reaching $195.74.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 62 days from now.</li>
</ul>
<h3>What The Experts Say On Danaher</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $243.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Baird keeps a Outperform rating on Danaher with a target price of $225. 
&#x2A; Maintaining their stance, an analyst from JP Morgan continues to hold a Overweight rating for Danaher, targeting a price of $260. 
&#x2A; An analyst from RBC Capital has revised its rating downward to Outperform, adjusting the price target to $250. 
&#x2A; In a cautious move, an analyst from Guggenheim downgraded its rating to Buy, setting a price target of $250. 
&#x2A; An analyst from Jefferies has decided to maintain their Buy rating on Danaher, which currently sits at a price target of $230. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Danaher, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Markets

Market Whales and Their Recent Bets on DHR Options

Looking into the current session, Danaher Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) shares are trading at $197.77, after a 0.69% spike. Moreover, over the past month, the stock increased by 2.97%, but in the past year, decreased by 25.98%. Shareholders might be interested in knowing whether the stock is undervalued, even if the company is performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1747778422_0.png" alt="Past Year Chart" />

<h3>A Look at Danaher P/E Relative to Its Competitors</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Danaher has a lower P/E than the aggregate P/E of 44.52 of the Life Sciences Tools &amp; Services industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1747778422_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

P/E Ratio Insights for Danaher

<ul>
<li>N of 1 therapy uniquely developed, on demand, for infant with life-threatening rare metabolic disorder in six months</li>
<li>Results published in The New England Journal of Medicine and showcased at American Society of Gene &amp; Cell Therapy Annual Meeting</li>
</ul>
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.aldevron.com&amp;esheet=54255056&amp;newsitemid=20250514568719&amp;lan=en-US&amp;anchor=Aldevron&amp;index=1&amp;md5=f817bb3d6d74ace1490fe4a80bca7115">Aldevron</a>, a global leader in the production of DNA, RNA and protein, together with <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.idtdna.com&amp;esheet=54255056&amp;newsitemid=20250514568719&amp;lan=en-US&amp;anchor=Integrated+DNA+Technologies&amp;index=2&amp;md5=3ebfea33eaf0cf1493d0e4f15900af7e">Integrated DNA Technologies</a> (IDT), a global leader in genomics solutions, announced the successful manufacture of the world's first personalized CRISPR gene editing drug product to treat an infant with urea cycle disorder (UCD). With no current cure for UCDs, the Children's Hospital of Philadelphia (CHOP) and the University of Pennsylvania (Penn) engaged Aldevron and IDT, both part of <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.danaher.com&amp;esheet=54255056&amp;newsitemid=20250514568719&amp;lan=en-US&amp;anchor=Danaher+Corporation&amp;index=3&amp;md5=16d1e6e69c20a6d0ce98005bd100f544">Danaher Corporation</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) to manufacture a novel mRNA-based personalized CRISPR therapy in six months—three times faster than the standard timeline for gene editing drug products.

Aldevron And Integrated DNA Technologies Manufacture World's First mRNA-Based Personalized CRISPR Gene Editing Drug Product To Treat Infant With Urea Cycle Disorder

Making a noteworthy insider sell on May 14, Steven M Rales, Chairman at Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>), is reported in the latest SEC filing.
What Happened: Rales's decision to sell 1,250,000 shares of Danaher was revealed in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000313616/000095017025071618//Archives/edgar/data/313616/000095017025071618/0000950170-25-071618-index.htm">U.S. Securities and Exchange Commission</a> on Wednesday. The total value of the sale is $245,919,390.
In the Thursday's morning session, Danaher's shares are currently trading at $187.0, experiencing a down of 0.44%.
<h3>Unveiling the Story Behind Danaher</h3>
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life science and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.
<h3>Danaher's Financial Performance</h3>
Negative Revenue Trend: Examining Danaher's financials over 3 months reveals challenges. As of 31 March, 2025, the company experienced a decline of approximately -0.95% in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Evaluating Earnings Performance:
<ul>
<li>
Gross Margin: Achieving a high gross margin of 61.16%, the company performs well in terms of cost management and profitability within its sector.
</li>
<li>
Earnings per Share (EPS): Danaher's EPS outshines the industry average, indicating a strong bottom-line trend with a current EPS of 1.33.
</li>
</ul>
Debt Management: Danaher's debt-to-equity ratio is below the industry average. With a ratio of 0.32, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Valuation Metrics: A Closer Look
<ul>
<li>
Price to Earnings (P/E) Ratio: The Price to Earnings ratio of 36.4 is lower than the industry average, indicating potential undervaluation for the stock.
</li>
<li>
Price to Sales (P/S) Ratio: With a relatively high Price to Sales ratio of 5.76 as compared to the industry average, the stock might be considered overvalued based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): At 20.84, the company's EV/EBITDA ratio outperforms industry norms, reflecting positive market perception. This positioning indicates optimistic expectations for the company's future performance.
</li>
</ul>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Relevance of Insider Transactions</h3>
Insider transactions shouldn't be used primarily to make an investing decision, however, they can be an important factor for an investor to consider.
Exploring the legal landscape, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated by Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and major hedge funds. These insiders are required to report their transactions through a Form 4 filing, which must be submitted within two business days of the transaction.
Highlighted by a company insider's new purchase, there's a positive anticipation for the stock to rise.
But, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>A Deep Dive into Insider Transaction Codes</h3>
When analyzing transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> tend to focus on those in the open market, detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase,while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000313616">Check Out The Full List Of Danaher's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Steven M Rales Takes Money Off The Table, Sells $245.92M In Danaher Stock

Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) has outperformed the market over the past 10 years by 2.11% on an annualized basis producing an average annual return of 12.39%. Currently, Danaher has a market capitalization of $135.78 billion. 
Buying $100 In DHR: If an investor had bought $100 of DHR stock 10 years ago, it would be worth $323.32 today based on a price of $189.73 for DHR at the time of writing.
<h3>Danaher's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746822613_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today

A large exercise of company stock options by Christopher Paul Riley, Executive Vice President at Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) was disclosed in a new SEC filing on May 1, as part of an insider exercise.
What Happened: Disclosed in a Form 4 filing on Thursday with the <a href="https://www.sec.gov/Archives/edgar/data/0000313616/000031361625000108//Archives/edgar/data/313616/000031361625000108/0000313616-25-000108-index.htm">U.S. Securities and Exchange Commission</a>, Riley, Executive Vice President at Danaher, executed a strategic derivative sale. This involved exercising stock options for 7,801 shares of DHR, resulting in a transaction value of $955,856.
Danaher shares are trading up 1.16% at $199.0 at the time of this writing on Friday morning. Since the current price is $199.0, this makes Riley's 7,801 shares worth $955,856.
<h3>Discovering Danaher: A Closer Look</h3>
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life science and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.
<h3>Key Indicators: Danaher's Financial Health</h3>
Revenue Challenges: Danaher's revenue growth over 3 months faced difficulties. As of 31 March, 2025, the company experienced a decline of approximately -0.95%. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Key Insights into Profitability Metrics:
<ul>
<li>
Gross Margin: The company sets a benchmark with a high gross margin of 61.16%, reflecting superior cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Danaher's EPS is significantly higher than the industry average. The company demonstrates a robust bottom-line performance with a current EPS of 1.33.
</li>
</ul>
Debt Management: Danaher's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.32.
Financial Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: The current P/E ratio of 38.12 is below industry norms, indicating potential undervaluation and presenting an investment opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: With a higher-than-average P/S ratio of 6.03, Danaher's stock is perceived as being overvalued in the market, particularly in relation to sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): At 21.73, the company's EV/EBITDA ratio outperforms industry norms, reflecting positive market perception. This positioning indicates optimistic expectations for the company's future performance.
</li>
</ul>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Impact of Insider Transactions on Investments</h3>
Insider transactions serve as a piece of the puzzle in investment decisions, rather than the entire picture.
When discussing legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated in Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are required to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
A new purchase by a company insider is a indication that they anticipate the stock will rise.
On the other hand, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Understanding Crucial Transaction Codes</h3>
<a href="https://www.benzinga.com/money/investing-tools">Investors</a> prefer focusing on transactions that take place in the open market, indicated in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S indicates a sale. Transaction code C indicates the conversion of an option, and transaction code A indicates grant, award or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000313616">Check Out The Full List Of Danaher's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

At Danaher, Christopher Paul Riley Chooses To Exercise Options, Resulting In $955K

<ul>
<li>Kytopen and Aldevron announce collaboration to expedite cell therapy manufacturing by combining their novel technologies.</li>
<li>High transgene expression and improved safety profile of Aldveron's Nanoplasmid&#x2122;&nbsp;vector technology and the gentle gene-delivery of Kytopen's Flowfect Tx&#x2122; platform with unlimited scale, together offer enhanced CRISPR-mediated T-cell engineering resulting in high yields.</li>
<li>A poster summarizing the data will be presented at ISCT, May 7-10, 2025, in New Orleans.</li>
</ul>
CAMBRIDGE, Mass. and FARGO, N.D., April 29, 2025 /PRNewswire/ --&nbsp;Kytopen Corp., a leader in providing non-viral, continuous flow cellular engineering technologies and Aldevron, a leading global manufacturer serving organizations in the gene editing, mRNA vaccine and therapeutics, viral gene therapy, and modified gene therapy spaces; today announced,&nbsp;a joint marketing agreement aimed at enhancing the workflow solutions for cell therapy manufacturers. The collaboration will focus on the joint promotion of the synergies achieved by combining the Aldveron Nanoplasmid&#x2122; vector technology with Kytopen's Flowfect Tx&#x2122; GMP cellular engineering platform in CRISPR-mediated engineering of primary T Cells.

Kytopen And Aldevron Announce Joint Marketing Agreement To Enhance Workflow Solutions For Cell Therapy Manufacturers

Whales with a lot of money to spend have taken a noticeably bearish stance on Danaher.
Looking at options history for Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) we detected 16 trades.
If we consider the specifics of each trade, it is accurate to state that 37% of the investors opened trades with bullish expectations and 56% with bearish.
From the overall spotted trades, 14 are puts, for a total amount of $1,099,493 and 2, calls, for a total amount of $324,480.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $170.0 to $210.0 for Danaher over the recent three months. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Danaher's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Danaher's whale activity within a strike price range from $170.0 to $210.0 in the last 30 days. 
<h3>Danaher Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745604051_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>DHR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/25/25</td>
<td>$27.2</td>
<td>$26.3</td>
<td>$27.04</td>
<td>$170.00</td>
<td>$246.0K</td>
<td align="right">127</td>
<td align="right">92</td>
</tr>
<tr>
<td>DHR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$16.2</td>
<td>$16.2</td>
<td>$16.2</td>
<td>$210.00</td>
<td>$105.5K</td>
<td align="right">866</td>
<td align="right">418</td>
</tr>
<tr>
<td>DHR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$17.7</td>
<td>$16.7</td>
<td>$17.23</td>
<td>$210.00</td>
<td>$103.2K</td>
<td align="right">866</td>
<td align="right">118</td>
</tr>
<tr>
<td>DHR</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$17.5</td>
<td>$15.8</td>
<td>$16.94</td>
<td>$210.00</td>
<td>$101.6K</td>
<td align="right">866</td>
<td align="right">241</td>
</tr>
<tr>
<td>DHR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$16.5</td>
<td>$15.8</td>
<td>$15.7</td>
<td>$210.00</td>
<td>$97.3K</td>
<td align="right">866</td>
<td align="right">539</td>
</tr>
</tbody>
</table>

<h3>About Danaher</h3>
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life science and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.
After a thorough review of the options trading surrounding Danaher, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Danaher's Current Market Status</h3>
<ul>
<li>Trading volume stands at 1,116,247, with DHR's price up by 0.15%, positioned at $196.79.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 88 days.</li>
</ul>
<h3>What Analysts Are Saying About Danaher</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $239.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from UBS persists with their Buy rating on Danaher, maintaining a target price of $240. 
&#x2A; In a cautious move, an analyst from RBC Capital downgraded its rating to Outperform, setting a price target of $250. 
&#x2A; An analyst from Baird has decided to maintain their Outperform rating on Danaher, which currently sits at a price target of $225. 
&#x2A; An analyst from Jefferies persists with their Buy rating on Danaher, maintaining a target price of $230. 
&#x2A; In a cautious move, an analyst from Guggenheim downgraded its rating to Buy, setting a price target of $250. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Danaher, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) has outperformed the market over the past 10 years by 3.44% on an annualized basis producing an average annual return of 13.45%. Currently, Danaher has a market capitalization of $140.63 billion. 
Buying $100 In DHR: If an investor had bought $100 of DHR stock 10 years ago, it would be worth $351.30 today based on a price of $196.50 for DHR at the time of writing.
<h3>Danaher's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745528418_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Danaher's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) short percent of float has fallen 22.13% since its last report. The company recently reported that it has 6.03 million shares sold short, which is 0.95% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.77 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Danaher Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745521224_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Danaher has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Danaher's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Danaher's peer group average for short interest as a percentage of float is 6.62%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Is The Market Feeling About Danaher?

Danaher Corp&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) on Tuesday reported first-quarter 2025 sales of $5.74 billion, down 1% year-over-year, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $5.59 billion</a>.&nbsp;
Non-GAAP core revenue was flat compared to the expectations of a decline by a low-single-digit percentage year-over-year&nbsp;<a target="_blank" href="https://www.benzinga.com/news/earnings/25/01/43298036/danaher-q4-eps-miss-expectations-amid-diagnostics-segment-lag" rel="noreferrer noopener">in the first quarter</a>.
Danaher reported second-quarter adjusted EPS of $1.88,&nbsp;down from $1.92 a year ago,&nbsp;<a target="_blank" href="https://www.benzinga.com/general/health-care/25/04/44921061/danaher-beats-q1-expectations-signals-caution-ahead-in-unusual-times" rel="noreferrer noopener">beating the consensus of $1.64</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44938778/danaher-pricing-strategy-key-to-navigating-tariff-challenges-analyst" rel="noreferrer noopener">Danaher Pricing Strategy Key To Navigating Tariff Challenges: Analyst</a>
Stifel on Tuesday wrote, &#8220;DHR&#8217;s start to the year was solid, as the company posted a beat and gave positive commentary around arguably the two most trending topics: bioprocess – where the upside case has started to materialize, and tariff impacts – which appear manageable in that they can be largely offset.&#8221;
Analyst Daniel Arias says customer demand looks strong for CDMOs and big pharma. China and smaller biotech firms are still behind, even though there&#8217;s some talk of stabilization. Overall, Stifel still sees a solid case for bioprocessing growth in 2025, possibly reaching double-digit levels.
The analyst maintains the Buy rating with a <a target="_blank" href="https://www.benzinga.com/quote/DHR/analyst-ratings" rel="noreferrer noopener">price target of $260</a>.
DHR&#8217;s stock valuation &#8220;has been a challenge for us,&#8221; the analyst wrote. Shares have sported a meaningful premium despite key businesses not having rebounded from &#8220;the 2023/2024 slowdown in biopharma.&#8221;
Stifel says management's guidance for 2025 disappointed many investors, which has brought valuation to a more approachable level.
&#8220;We believe estimates can move higher both in 2025 and 2026,&#8221; Arias said. 
The analysts see an opportunity to own DHR ahead of sentiment and end market improvement, which can yield upside for the stock.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/04/44954335/old-dominion-earnings-shine-despite-revenue-slide" target="_blank" rel="noreferrer noopener">Old Dominion Earnings Shine Despite Revenue Slide, CEO Blames &#8216;Ongoing Softness&#8217; In Economy</a></li>
</ul>
Image: Shutterstock

Large Cap

Analyst Sees Opportunity In Danaher Stock As Sentiment Improves

RBC Capital analyst Conor McNamara reiterates Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) with a Outperform and maintains $250 price target.

RBC Capital Reiterates Outperform on Danaher, Maintains $250 Price Target

Goldman Sachs analyst Matthew Sykes maintains Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) with a Buy and lowers the price target from $260 to $240.

Goldman Sachs Maintains Buy on Danaher, Lowers Price Target to $240

Guggenheim analyst Subbu Nambi reiterates Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) with a Buy and maintains $250 price target.

Guggenheim Reiterates Buy on Danaher, Maintains $250 Price Target

UBS analyst Dan Leonard maintains Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) with a Buy and lowers the price target from $275 to $240.

UBS Maintains Buy on Danaher, Lowers Price Target to $240

Press Releases

Danaher Schedules First Quarter 2025 Earnings Conference Call

Danaher Reports First Quarter 2025 Results

Kytopen and Aldevron Expedite Cell Therapy Manufacturing Through Their Collaborative CRISPR-mediated Cellular Engineering Workflow

Dividends

Danaher Announces Quarterly Dividend

Danaher to Present at Bank of America Securities Healthcare Conference

Aldevron and Integrated DNA Technologies Manufacture World's First mRNA-based Personalized CRISPR Therapy

Danaher Announces Diagnostic Development and Commercialization Partnership to Scale Precision Medicine

SCIEX Sets a New Standard in Accurate Mass Quantitation With the ZenoTOF 8600 System and New Software Collaborations

SCIEX and Evosep expand access to standardized proteomics for Pharma and Biotech with new reseller agreement

Software Launches for SCIEX OS Ecosystem to Help Scientists Accelerate Discoveries and Streamline Lab Operations

Agilent Technologies

AbCellera Biologics

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Avantor

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

BioLife Solutions

Bruker

Charles River Laboratories International, Inc. Common Stock

Charles River

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Evotec

Illumina

IQVIA Hldgs

Medpace Hldgs

Mettler-Toledo International, Inc. Common Stock

Mettler-Toledo Intl

Niagen Bioscience

Repligen

Revvity

Sotera Health

Stevanato Group

Bio-Techne

Tempus AI

Thermo Fisher Scientific Inc Common Stock

Thermo Fisher Scientific

10x Genomics

Waters

West Pharmaceutical Services, Inc. Common Stock

West Pharmaceutical Servs

RBC Capital

Goldman Sachs

Guggenheim

Baird

매주, 벤징가의 스톡 위스퍼 지수(Benzinga's Stock Whisper Index)는 독점 데이터(proprietary data)와 패턴 인식의 조합을 사용하여 <a href="https://www.benzinga.com/topic/stock-whisper-index" target="_blank" rel="noreferrer noopener">표면 바로 아래에서 주목</a>을 받을 만한 주식 5종목을 소개한다.
투자자들은 가치가 저평가된, 관심이 적은, 새로운 주식들을 항상 찾고 있다. 소매 거래자들이 사용할 수 있는 방법은 무수히 많기 때문에 새로운 기회를 발견하고 특정 주식이 관심을 가져야 하는 이유를 이해하기 위해 풍부한 정보를 조사하는 것이 어려운 경우가 많다.
다음은 12월 13일로 끝나는 주간의 벤징가 ‘스톡 위스퍼' 지수의 개요:
1. 스냅 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>):
<div class="ticker-wrapper">
<div class="sc-icgYrN gsJcQM ticker-box-wrapper">
<div>
<div class="relative w-fit"></div>
</div>
<div class="sc-hZlppA ddOBfh get-report-button flex">
<div class="flex items-center ml-2 text-sm text-blue-500">소셜 미디어 및 메신저 회사인 스냅은 벤징가 독자들로부터 강한 관심을 받았다. 이는 미국에서 틱톡 <a style="font-size: revert;" href="https://www.benzinga.com/24/12/42369266/meta-reddit-stocks-climb-record-highs-as-tiktoks-battle-against-us-ban-continues-after-court-ruling" target="_blank" rel="noopener">금지 운동이 계속되고 있는 것</a>과 관련이 있을 가능성이 크다.</div>
</div>
</div>
</div>
스냅과 틱톡의 소셜 미디어 경쟁자인 페이스북, 인스타그램 및 레딧 등은 틱톡이 금지될 경우 이점을 누릴 수 있다. 최근 틱톡은 미국 항소 법원과의 싸움에서 패배했으며, 모회사 바이트댄스는 2025년 1월 19일까지 미국 자회사를 비중국인 소유자에게 매각하지 않으면 앱 스토어에서 플랫폼이 제거된다는 기한을 받았다.
이것이 스냅에게는 긍정적인 소식이 될 수 있지만, 금지 조치는 아직 끝나지 않았으며, 바이트댄스가 계속해서 싸울 것이란 우려와 함께 도널드 트럼프 대통령 당선자가 백악관을 인수할 때 금지 조치를 중단할 수 있다는 우려도 있다. 또한 스냅과 다른 소셜 미디어 플랫폼들은 <a href="https://www.benzinga.com/24/11/42237670/meta-tiktok-snapchat-could-face-32m-fines-as-australia-enforces-social-media-ban-for-under-16s-while-exempting-youtube" target="_blank" rel="noopener">여러 국가</a>와 주들에서 사용 연령 제한으로 인해 중단 조치를 받을 수 있다. 주가가 더 하락할 수 있다.
스냅의 주가는 금요일 0.62% 하락한 11.31달러에 마감되었다. 이번 주에는 9.52% 하락했으며, 2024년 연초 대비 주가가 29.93% 하락했다.
<img decoding="async" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13134037/Screenshot-268.png?optimize=medium&amp;dpr=1.25&amp;auto=webp&amp;width=2048" />
2. 실스크 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAES#NASDAQ">LAES</a>):
마이크로칩 회사인 실스크(SEALSQ)는 드론과 관련된 여러 뉴스로 인해 주가가 급등했다. 이 회사는 패럿(Parrot)과 에이지이글(AgEagle)과의 <a href="https://www.benzinga.com/trading-ideas/movers/24/12/42447155/sealsq-corp-shares-are-up-by-more-than-90-what-you-need-to-know" target="_blank" rel="noopener">파트너십을 발표</a>했다.
이 회사는 2025년에 새로운 양자 저항 보안 칩 포트폴리오를 출시할 계획이다. 이로 인해 주가가 Benzinga 독자들의 주목을 받을 수 있게 된다. 이러한 칩에 대한 테스트가 진행 중이며, 실스크는 IC 알프스(IC&#8217;ALPS)와의 <a href="https://www.benzinga.com/24/12/42466578/whats-going-on-with-sealsq-corp-today" target="_blank" rel="noopener">파트너십을 발표</a>하여 보안 애플리케이션 전용 집적 회로의 개발을 가속화했다.
&#8220;우리는 민첩성과 혁신을 결합함으로써 글로벌 반도체 산업에서 우수성의 기준을 설정하고 있다&#8221;고 실스크의 CTO인 장 피에르 앙구앙(Jean Pierre Enguent)가 말했다.
드론 시장은 상업용 및 군용 드론 애플리케이션의 증가로 인해 투자자들이 주목하고 있는 핫한 시장이다. 실스크의 주가는 이번 주에 297.82% 급등했다. 금요일 이 주식은 5.41% 하락한 1.75달러에 마감했으나 이후 시간외 거래에서 10.29% 급등했다.
<img decoding="async" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13134056/Screenshot-269.png?optimize=medium&amp;dpr=1.25&amp;auto=webp&amp;width=2048" />
3. 버티브 홀딩스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRT#NYSE">VRT</a>):
필수 전력 및 인프라 회사인 버티브(Vertiv)는 이번 주에 독자들로부터 강한 관심을 받았다.
뱅크 오브 아메리카의 애널리스트인 앤드류 오빈(Andrew Obin)은 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/42072226/vertivs-earnings-estimates-raised-by-analyst-amid-improved-margin-outlook" target="_blank" rel="noopener">최근 주식에 대해 매수 등급을 재확인</a>하고 목표 주가를 150달러로 설정했다. 이 애널리스트는 이 회사가 2024년부터 2029년까지의 유기적 매출 성장 전망을 12%-14%로 상향 조정했다고 밝혔다. 다른 애널리스트들도 최근 버티브에 대한 의견을 추가했으며, 바클레이즈는 주식을 중립 등급으로 시작하고 목표 주가를 142달러로 <a href="https://www.benzinga.com/quote/VRT/analyst-ratings" target="_blank" rel="noopener">설정</a>했으며, 씨티그룹은 매수 등급을 유지하고 목표 주가를 141달러에서 155달러로 상향 조정했다.
<img decoding="async" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13134111/Screenshot-270.png?optimize=medium&amp;dpr=1.25&amp;auto=webp&amp;width=2048" />
4. 다나허 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>):
과학 기기 제조 회사인 다나허(Danaher)는 이번 주에 독자들로부터 증가된 관심을 받았다.
이 주식은 이전에 <a href="https://www.benzinga.com/top-stories/24/06/39551432/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet" target="_blank" rel="noopener">6월에</a> 주식 속삭임 지수에 등장했으며, 애널리스트의 업그레이드가 주가를 상승시켰다. 뱅크 오브 아메리카는 중립에서 매수로 주식을 상향 조정하고, 목표 주가를 290달러로 설정했다. 이 애널리스트는 전략적 파트너십과 가격 책정이 향후 성장에 기여할 수 있다고 말했다.
다나허는 3분기 재무 결과를 10월에 발표했으며, 주당 순이익과 매출 모두 시장 예상을 초과했다. 이 회사는 매출과 주당 순이익 모두에서 10분기 연속으로 애널리스트 예상을 초과했다. 4분기 실적은 1월에 발표될 예정이며, 이는 주식에 대한 미래 촉매제가 될 수 있다.
<img decoding="async" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13134125/Screenshot-271.png?optimize=medium&amp;dpr=1.25&amp;auto=webp&amp;width=2048" />
5. 마벨 테크놀로지 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>):
반도체 주식인 마벨은 동료들이 실적을 발표하고 회사가 12월 3일에 3분기 <a href="https://kr.benzinga.com/news/usa/stocks/%EB%A7%88%EB%B2%A8-%ED%85%8C%ED%81%AC%EB%86%80%EB%A1%9C%EC%A7%80-3%EB%B6%84%EA%B8%B0-%ED%98%B8%EC%8B%A4%EC%A0%81-%EB%B0%8F-4%EB%B6%84%EA%B8%B0-%EA%B0%95%EB%A0%A5%ED%95%9C-%EC%A0%84%EB%A7%9D-%EB%B0%9C/" target="_blank" rel="noopener">재무 결과를 발표</a>한 지 2주도 채 안 된 시점에서 주가가 상승하고 있다. 이 회사는 매출과 주당 순이익 모두에서 애널리스트의 예상치를 초과했다.
마벨의 CEO 맷 머피(Matt Murphy)는 회사의 4분기 전망이 맞춤형 AI 실리콘 프로그램의 대량 생산에 의해 주도되고 있음을 강조했다. 이 회사는 최근 데이터 센터를 위한 새로운 인터커넥트 포트폴리오 칩의 <a href="https://www.benzinga.com/news/contracts/24/12/42432652/marvell-debuts-game-changing-lpo-chipset-for-data-centers-details" target="_blank" rel="noopener">가용성을 발표</a>했다. 이는 AI 기반 데이터 센터가 인터커넥트 솔루션 최적화의 필요성을 높일 수 있기 때문이다.
여러 애널리스트들은 이 회사의 3분기 재무 결과 발표 후 <a href="https://www.benzinga.com/news/earnings/earnings-beats/24/12/42321281/marvell-technology-posts-solid-q3-beat-analysts-raise-forecasts-expect-40-50-earnings-growth" target="_blank" rel="noopener">주가 목표를 상향 조정</a>했다. 금요일 이 주식은 10.79% 급등한 120.77달러에 마감되었다. 주가는 2024년 연초 대비 107.62% 상승했다.
<img decoding="async" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13134140/Screenshot-272.png?optimize=medium&amp;dpr=1.25&amp;auto=webp&amp;width=2048" />
다음 주 보고서를 계속 지켜봐 주시기 바랍니다. <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent111524&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">여기에서</a> Benzinga Pro를 팔로우하여 모든 최신 헤드라인과 시장을 움직이는 주요 기사를 확인하세요.
여기에서 최근 ‘스톡 위스퍼 지수' 보고서를 읽어보세요.
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EB%B2%A4%EC%A7%95%EA%B0%80%EC%9D%98-%EC%8A%A4%ED%86%A1-%EC%9C%84%EC%8A%A4%ED%8D%BC-%EC%A7%80%EC%88%98-%ED%94%84%EB%A1%9C%ED%83%80%EB%9D%BC-%EB%A7%88%EB%9D%BC-%ED%8A%B8%EB%A0%88/" target="_blank" rel="noopener">12월 7일</a></li>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EB%B2%A4%EC%A7%95%EA%B0%80%EC%9D%98-%EC%8A%A4%ED%86%A1-%EC%9C%84%EC%8A%A4%ED%8D%BC-%EC%A7%80%EC%88%98-%EC%82%AC%EC%9D%B4%EB%A8%BC-%ED%94%84%EB%A1%9C%ED%8D%BC%ED%8B%B0-%EC%95%A8%EB%A6%AC/" target="_blank" rel="noreferrer noopener">11월 30일</a></li>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EB%B2%A4%EC%A7%95%EA%B0%80%EC%9D%98-%EC%8A%A4%ED%86%A1-%EC%9C%84%EC%8A%A4%ED%8D%BC-%EC%A7%80%EC%88%98-%EB%8D%B8%ED%83%80-%ED%95%AD%EA%B3%B5-%EB%82%98%EC%9D%B4%ED%82%A4-%EC%98%A4%ED%86%A0/" target="_blank" rel="noreferrer noopener">11월 23일</a></li>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EB%B2%A4%EC%A7%95%EA%B0%80%EC%9D%98-%EC%8A%A4%ED%86%A1-%EC%9C%84%EC%8A%A4%ED%8D%BC-%EC%A7%80%EC%88%98-%EC%95%A1%EC%86%90-%EC%8A%A4%EB%85%B8%EC%9A%B0%ED%94%8C%EB%A0%88%EC%9D%B4-%EC%97%A0/" target="_blank" rel="noreferrer noopener">11월 16일</a></li>
</ul>
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

벤징가의 '스톡 위스퍼' 지수: 스냅, 실스크, 버티브, 다나허 및 마벨 테크놀로지

화요일에, 다나허(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>)는 3분기 매출이 57억 9천만 달러로 전년 대비 3% 증가했으며, <a href="https://www.benzinga.com/news/earnings/24/10/41449367/life-science-giant-danaher-q3-earnings-revenue-and-eps-beat-sticks-to-annual-guidance" target="_blank" rel="noreferrer noopener">컨센서스 55억 9천만 달러</a>를 상회했다고 보고했다.
가이던스: 다나허(Danaher)는 2024 회계연도 비GAAP 핵심 매출이 전년 대비 낮은 한 자릿수로 감소할 것임을 재확인했다.
이 회사는 2024년 바이오프로세싱 핵심 매출이 낮은 한 자릿수로 감소할 것으로 예상하고 있으며, 세파이드(Cepheid) 2024 호흡기 매출은 이전 지침 16억 달러에 비해 약 17억 달러가 될 것으로 예상한다.
윌리엄 블레어(William Blair)는 도나허의 3분기 실적이 특히 바이오프로세싱의 지속적인 회복과 관련하여 기대에 부합했다고 보고했다. 그러나 자본 지출은 여전히 약세이다.
이 애널리스트는 회복 테마가 예상대로 진행되고 있으며, 결과가 분기 중 산업 컨퍼런스 업데이트에서 본 유사한 트렌드를 반영하고 있다고 강조했다.
3분기 B2B는 약 1.0배로 개선되어 1년 전의 0.80배에서 상승했으며 순차 주문의 높은 한 자릿수 증가가 바이오프로세싱 반등을 더욱 뒷받침했다.
장비 부문에서 생명과학 장비는 예측 및 분기 내 관찰과 일치하여 한 자릿수 중반 감소를 보였다.
한편, 진단 부문은 잘 수행되었으며, 세파이드의 호흡기 매출은 다시 한 번 기대를 초과했다.
가이던스에 대해 경영진은 생명공학 분야의 4분기에 중간에서 높은 한 자릿수 핵심 성장률을 기대한다. 이 애널리스트는 컨퍼런스 콜의 초점이 바이오프로세싱의 4분기 종료율, 2025년 초기 통찰력, 자본 장비의 약세 및 중국에 대한 업데이트된 생각이 될 것으로 예상하고 있다.
윌리엄 블레어는 아웃퍼폼 등급을 유지하고 있다. 골드만삭스는 중립 등급을 유지하며, <a href="https://www.benzinga.com/quote/dhr/analyst-ratings">목표 주가를 250달러로 설정</a>했다.
주가 움직임: 다나허의 주식은 화요일 3.97% 하락한 261.28달러에 마감되었다.
사진 출처: Shutterstock
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

이들 11개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
<ol>
<li>QXO(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QXO#NASDAQ">QXO</a>)의 주가는 <a href="https://www.benzinga.com//node/39880836" target="_blank" rel="noreferrer noopener">사모 금융 유치</a>를 발표한 이후 33.37% 상승했다.</li>
<li>아반토(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVTR#NYSE">AVTR</a>)의 주식은 S&amp;P MidCap 400에 편입된다는 발표 이후 지난 주에 21.62% 상승했다. 또한 예상보다 나은 2분기 실적을 발표했다.</li>
<li>유니버셜 헬스 서비스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UHS#NYSE">UHS</a>)는 회사가 예상보다 나은 2분기 실적을 발표하고 <a href="https://www.benzinga.com//node/39942622" target="_blank" rel="noreferrer noopener">2024 회계연도 지침을</a> 상향 조정한 후 주가가 17.73% 상승했다.</li>
<li>맨하탄 어소시에이츠(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MANH#NASDAQ">MANH</a>)의 주가는 예상보다 나은 2분기 재무 결과를 보고한 후 17.02% 상승했다. 몇몇 분석가들은 주식에 대한 가격 <a href="https://www.benzinga.com/quote/MANH/analyst-ratings" target="_blank" rel="noreferrer noopener">예측</a>을 높였다.</li>
<li>몰리나 헬스케어(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>)의 주가는 <a href="https://www.benzinga.com//node/39942485" target="_blank" rel="noreferrer noopener">예상보다 좋은 2분기 실적</a>에 힘입어 15.53% 상승했다.</li>
<li>퍼스트 시티즌스 뱅크셰어스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCNCA#NASDAQ">FCNCA</a>)의 주가는 회사의 분기 실적이 예상보다 높았음을 보고한 후 15.15% 상승했다.</li>
<li>테넷 헬스케어(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>)는 예상보다 나은 2분기 재무 결과를 보고한 후 주가가 13.02% 상승했으며, 회사는 FY24 지침을 추정치보다 높이고 3분기 지침을 추정치보다 높게 발표했다. 또한 회사는 <a href="https://www.benzinga.com//node/39934114" target="_blank" rel="noreferrer noopener">15억 달러 규모의</a> 자사주 매입을 승인했다고 발표했다.</li>
<li>CBRE 그룹(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CBRE#NYSE">CBRE</a>)은 회사가 2024년 목표를 상향 조정한 후 지난 주 주가가 12.99% 상승했다. 몇몇 분석가들은 주식에 대한 가격 <a href="https://www.benzinga.com/quote/MANH/analyst-ratings" target="_blank" rel="noreferrer noopener">예측</a>을 높였다.</li>
<li>써모 피셔 사이언티픽(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>)의 주가는 지난주 12.63% 상승했다. 이 회사는 연간 전망을 <a href="https://www.benzinga.com//node/39930516" target="_blank" rel="noreferrer noopener">상향 조정</a>했다.</li>
<li>다나허(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>)의 주가는 회사가 예상보다 나은 2분기 실적을 보고한 후 11.30% 상승하여 더 높게 거래되고 있다.</li>
<li>록히드 마틴(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>)의 주가는 긍정적인 애널리스트 <a href="https://www.benzinga.com//node/39941283" target="_blank" rel="noreferrer noopener">평가와 강한 2분기 실적</a>에 힘입어 10.72% 상승했다.</li>
</ol>
다음 기사:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%ed%8f%ac%eb%93%9c-%ec%8a%a4%ed%85%94%eb%9e%80%ed%8b%b0%ec%8a%a4-%eb%b0%8f-%eb%8d%b8%ec%9d%80-%ec%a7%80%eb%82%9c%ec%a3%bc-%ec%b5%9c%ec%95%85%ec%9d%98-%ec%84%b1%ea%b3%bc%eb%a5%bc-%eb%b3%b4%ec%9d%b8-12/" target="_blank" rel="noopener">포드, 스텔란티스 및 델은 지난주 최악의 성과를 보인 12개 대형주 중 일부 (7월 21일~7월 27일)</a></li>
</ul>
썸네일 제공: 셔터스톡
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Danaher

뉴스

에 대한 최신 뉴스 Danaher (NYSE:DHR) 주식

토요일, 12월 14, 2024

화요일, 10월 22, 2024

일요일, 7월 28, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌